{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:48:52Z","timestamp":1780044532204,"version":"3.53.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.urology.2021.08.017","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T10:50:12Z","timestamp":1629888612000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities"],"prefix":"10.1016","volume":"163","author":[{"given":"Kelly K.","family":"Bree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-901X","authenticated-orcid":false,"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2021.08.017_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2021.08.017_bib0002","first-page":"211","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2021.08.017_bib0003","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1002\/cncr.27379","article-title":"Explaining racial differences in prostate cancer mortality","volume":"118","author":"Taksler","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0004","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2014.59.8912","article-title":"Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer","volume":"33","author":"Yamoah","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0005","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cam4.1451","article-title":"African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015","volume":"7","author":"Williams","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/genes11121471","article-title":"The impact of African ancestry on prostate cancer disparities in the Era of precision medicine","volume":"11","author":"Lewis","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.urology.2021.08.017_bib0007","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","article-title":"Highly penetrant hereditary cancer syndromes","volume":"23","author":"Nagy","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2021.08.017_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2021.08.017_bib0009","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.urology.2021.08.017_bib0013","first-page":"1","article-title":"Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation","author":"Giri","year":"2017","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0014","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.bjc.6603929","article-title":"Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer","volume":"97","author":"Agalliu","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0015","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of prostate cancer in lynch syndrome: a systematic review and meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidem Biomar"},{"key":"10.1016\/j.urology.2021.08.017_bib0017","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0018","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2013.03.007","article-title":"Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24 213 cases and 73 631 controls","volume":"64","author":"Shang","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.017_bib0019","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 2.2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed March 29, 2021"},{"key":"10.1016\/j.urology.2021.08.017_bib0020","unstructured":"National Comprehensive Cancer Network. Prostate Cancer Early Detection (1.2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf. Accessed March 29, 2021"},{"key":"10.1016\/j.urology.2021.08.017_bib0021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.017_bib0022","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0023","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0024","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0025","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0026","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urology.2021.08.017_bib0027","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/ethnic disparities in genomic sequencing","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000367962","article-title":"Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease","volume":"18","author":"Peprah","year":"2015","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.urology.2021.08.017_bib0029","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1046","article-title":"A review of prostate cancer Genome-Wide Association Studies (GWAS)","volume":"27","author":"Benafif","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.urology.2021.08.017_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv431","article-title":"Prostate cancer susceptibility in men of African ancestry at 8q24","volume":"108","author":"Han","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2021.08.017_bib0032","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1073\/pnas.0605832103","article-title":"Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men","volume":"103","author":"Freedman","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urology.2021.08.017_bib0033","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ng1808","article-title":"A common variant associated with prostate cancer in European and African populations","volume":"38","author":"Amundadottir","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pros.22532","article-title":"Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans","volume":"73","author":"Bensen","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2021.08.017_bib0035","first-page":"1549","article-title":"Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men","volume":"35","author":"Jingwi","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urology.2021.08.017_bib0036","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/hmg\/ddv462","article-title":"Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk","volume":"25","author":"Rand","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0037","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng\/ml","volume":"65","author":"Nordstrom","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.017_bib0038","doi-asserted-by":"crossref","first-page":"17075","DOI":"10.1038\/s41598-020-74172-z","article-title":"Prostate cancer risk prediction using a polygenic risk score","volume":"10","author":"Sipeky","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.urology.2021.08.017_bib0039","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.017_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.09.010","article-title":"Ethnic disparities among men with prostate cancer undergoing germline testing","volume":"38","author":"Kwon","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0042","doi-asserted-by":"crossref","first-page":"440","DOI":"10.18632\/oncotarget.27456","article-title":"Inherited DNA-repair gene mutations in African American men with prostate cancer","volume":"11","author":"Sartor","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.urology.2021.08.017_bib0043","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/pros.23464","article-title":"Rare germline mutations in African American men diagnosed with early-onset prostate cancer","volume":"78","author":"Beebe-Dimmer","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2021.08.017_bib0044","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.bjc.6603929","article-title":"Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer","volume":"97","author":"Agalliu","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0045","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41391-018-0114-1","article-title":"Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population","volume":"22","author":"Petrovics","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2021.08.017_bib0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/PO.19.00179","article-title":"Pathogenic variants in cancer predisposition genes and prostate cancer risk in men of African ancestry","volume":"4","author":"Matejcic","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0047","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.urology.2021.08.017_bib0048","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jnci\/djaa132","article-title":"Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer","volume":"113","author":"Darst","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2021.08.017_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/mcs.a003657","article-title":"Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance","volume":"5","author":"Horak","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.urology.2021.08.017_bib0050","first-page":"15708","article-title":"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"5 Suppl 2","key":"10.1016\/j.urology.2021.08.017_bib0051","first-page":"12","article-title":"Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13","volume":"26","author":"Isaacs","year":"2019","journal-title":"Can J Urol"},{"key":"10.1016\/j.urology.2021.08.017_bib0052","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Human Genetics"},{"key":"10.1016\/j.urology.2021.08.017_bib0053","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.017_bib0054","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/cncr.31316","article-title":"Genetic testing for hereditary prostate cancer: current status and limitations","volume":"124","author":"Zhen","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","article-title":"Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European","volume":"18","author":"Ndugga-Kabuye","year":"2019","journal-title":"Fam Cancer"},{"key":"10.1016\/j.urology.2021.08.017_bib0056","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12687-017-0316-6","article-title":"Diversity and inclusion in genomic research: why the uneven progress?","volume":"8","author":"Bentley","year":"2017","journal-title":"J Community Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0057","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2105\/AJPH.87.11.1773","article-title":"Under the shadow of Tuskegee: African Americans and health care","volume":"87","author":"Gamble","year":"1997","journal-title":"Am J Public Health"},{"key":"10.1016\/j.urology.2021.08.017_bib0058","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12687-013-0155-z","article-title":"Community leaders' perspectives on engaging African Americans in biobanks and other human genetics initiatives","volume":"4","author":"Buseh","year":"2013","journal-title":"J Community Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0059","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s13187-014-0669-z","article-title":"Strategies for enrollment of African Americans into cancer genetic studies","volume":"30","author":"Ewing","year":"2015","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.urology.2021.08.017_bib0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/GIM.0b013e3181ab22aa","article-title":"Barriers to the use of genetic testing: a study of racial and ethnic disparities","volume":"11","author":"Suther","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0061","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000360472","article-title":"Intentions to donate to a biobank in a national sample of African Americans","volume":"17","author":"McDonald","year":"2014","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.urology.2021.08.017_bib0062","first-page":"46","article-title":"Factors affecting research participation in African American college students","volume":"40","author":"Diaz","year":"2008","journal-title":"Fam Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0063","unstructured":"American Urological Association. AUA 2019 Annual Census.https:\/\/www.auanet.org\/research\/research-resources\/aua-census\/census-results. Published 2019. Accessed April 3, 2021."},{"key":"10.1016\/j.urology.2021.08.017_bib0064","first-page":"17","article-title":"Minority, underrepresented groups working to bring diversity to research: All of Us partners engage communities","volume":"48","author":"Late","year":"2019","journal-title":"The Nation's Health"},{"key":"10.1016\/j.urology.2021.08.017_bib0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-019-05359-w","article-title":"Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations","volume":"178","author":"Ademuyiwa","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.urology.2021.08.017_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001387","article-title":"Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans","volume":"7","author":"Haiman","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.urology.2021.08.017_bib0067","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/pros.23368","article-title":"Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men","volume":"77","author":"Irizarry-Ramirez","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2021.08.017_bib0068","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/pros.22486","article-title":"8q24 risk alleles in West African and Caribbean men","volume":"72","author":"Murphy","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2021.08.017_bib0069","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1055-9965.EPI-09-0091","article-title":"Prostate cancer risk associated loci in African Americans","volume":"18","author":"Xu","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urology.2021.08.017_bib0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pros.22726","article-title":"A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry","volume":"74","author":"Chung","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2021.08.017_bib0071","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1038\/sj.onc.1206176","article-title":"Homologous repair of DNA damage and tumorigenesis:the BRCA connection","volume":"21","author":"Jasin","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2021.08.017_bib0072","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.urology.2021.08.017_bib0073","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/1541-7786.MCR-09-0123","article-title":"PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2","volume":"7","author":"Zhang","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.urology.2021.08.017_bib0074","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3390\/cells9122675","article-title":"CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate","volume":"9","author":"Stolarova","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.urology.2021.08.017_bib0075","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0960-9822(00)00256-6","article-title":"Developmental patterning. The Hox code out on a limb","volume":"4","author":"Graham","year":"1994","journal-title":"Curr Biol"},{"key":"10.1016\/j.urology.2021.08.017_bib0076","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.08.017_bib0077","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djs288","article-title":"Association between germline HOXB13 G84E mutation and risk of prostate cancer","volume":"104","author":"Akbari","year":"2012","journal-title":"J Natl Cancer Inst"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521007962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521007962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:43:40Z","timestamp":1758768220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429521007962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":77,"alternative-id":["S0090429521007962"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2021.08.017","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2021.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}